Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosis of NK-Large Granular Lymphocytic Leukemia.

Blood advances·2026
Same author

[Agranulocytose médicamenteuse].

La Revue du praticien·2026
Same author

Anti-PAD4 antibodies link autoimmunity to PAD4 with CTL-associated rheumatoid arthritis.

Annals of the rheumatic diseases·2026
Same author

Acid ceramidase inhibition enhances BCL-2 targeting in venetoclax-resistant acute myeloid leukemia.

Blood neoplasia·2026
Same author

Pharmacological blockade of rho kinase enhances venetoclax responses in translational models of acute myeloid leukemia.

Haematologica·2026
Same author

Advances in the treatment of large granular lymphocytic leukemia.

Expert review of hematology·2026

Related Experiment Video

Updated: Jun 5, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

How I treat LGL leukemia.

Thierry Lamy1, Thomas P Loughran

  • 1Department of Hematology, Pontchaillou University Hospital, Rennes, France. tloughran@psu.edu

Blood
|December 31, 2010
PubMed
Summary

Large granular lymphocyte (LGL) leukemia involves abnormal T or NK cells. Treatment focuses on managing symptoms like neutropenia and rheumatoid arthritis with immunosuppressants, as cures are unavailable.

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Large granular lymphocyte (LGL) leukemia is a clonal expansion of cytotoxic T or NK cells.
  • Clinical features include neutropenia, anemia, and rheumatoid arthritis (RA).
  • Pathogenesis involves chronic antigen stimulation, dysregulated apoptosis, and resistance to cell death.

Purpose of the Study:

  • To review the clinical features and treatment of T-LGL leukemia.
  • To discuss current therapeutic strategies and unmet needs.

Main Methods:

  • Review of clinical presentation and treatment outcomes.
  • Analysis of pathogenic mechanisms including immune dysregulation and cell survival factors.
  • Evaluation of initial and subsequent treatment options.

More Related Videos

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Related Experiment Videos

Last Updated: Jun 5, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Main Results:

  • T-LGL leukemia often requires treatment for neutropenia, anemia, or RA.
  • Low-dose methotrexate or oral cyclophosphamide are initial therapy options.
  • Cyclosporine is an alternative if initial treatments fail.

Conclusions:

  • T-LGL leukemia typically follows an indolent course, with infections being a rare cause of mortality.
  • Current treatments are immunosuppressive and not curative.
  • New therapeutic options are needed for T-LGL leukemia.